Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced <scp>HCC</scp> : An International Multicentre Study
Authors
- Ho Yeong Lim (ORCID: https://orcid.org/0000-0001-9325-2300)
- J -H Kim
- Hannah Yang (ORCID: https://orcid.org/0000-0003-2252-7041)
- Youngun Kim (ORCID: https://orcid.org/0000-0003-0264-5446)
- Chan Kim (ORCID: https://orcid.org/0000-0001-9780-6155)
- Chansik An
- Ilhwan Kim
- San‐Chi Chen
- Beodeul Kang
- David Tai
- Jeffrey Wong
- Hyeyeong Kim
- Hong Jae Chon
- Thomas Yau
- Su Jin Jang
- Masatoshi Kudo
Institutions
- Ulsan College (KR)
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- University of Ulsan (KR)
- Inje University Haeundae Paik Hospital (KR)
- CHA University Bundang Medical Center (KR)
- Ulsan University Hospital (KR)
- National Cancer Centre Singapore (SG)
- CHA University (KR)
- University of Hong Kong (HK)
- Kindai University (JP)
Publication Details
- Journal
- Liver International
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1111/liv.70493
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- National Research Foundation
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea